Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study

• Published in: Neurology Vol. 91; no. 24; p. e2211
• Main Authors: Detke, Holland C, Goadsby, Peter J, Wang, Shufang, Friedman, Deborah I, Selzler, Katherine J, Aurora, Sheena K
• Format: Journal Article
• Language: English
• Published: United States 11.12.2018
• Subjects: Adult; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Chronic Disease - prevention & control; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders - drug therapy; Treatment Outcome

To evaluate the efficacy and safety of galcanezumab, a humanized monoclonal antibody that selectively binds to calcitonin gene-related peptide, in the preventive treatment of chronic migraine. A phase 3, randomized, double-blind, placebo-controlled study of LY2951742 in patients with chronic migrain...